Opinion/decision on a Paediatric investigation plan (PIP): Emgality, Galcanezumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Neurology, PIP number: P/0030/2023

Opinion/decision on a Paediatric investigation plan (PIP): Symtuza, darunavir,cobicistat,emtricitabine,tenofovir alafenamide, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Infectious diseases, PIP number: P/0029/2023

Opinion/decision on a Paediatric investigation plan (PIP): Evotaz, cobicistat,atazanavir (sulfate), decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Infectious diseases, PIP number: P/0027/2023

Opinion/decision on a Paediatric investigation plan (PIP): Rezolsta, darunavir,cobicistat, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Infectious diseases, PIP number: P/0039/2023

EudraVigilance veterinary - Registration manual

Pharmacovigilance Risk Assessment Committee (PRAC): 23-26 October 2023, European Medicines Agency, Amsterdam, the Netherlands, 23 October 2023

Human medicines European public assessment report (EPAR): Azacitidine betapharm, azacitidine, Date of authorisation: 24/03/2020, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR): Ritonavir Mylan, ritonavir, Date of authorisation: 09/11/2017, Revision: 15, Status: Authorised

Human medicines European public assessment report (EPAR): Humalog, insulin lispro, Date of authorisation: 30/04/1996, Revision: 35, Status: Authorised

Workplan 2023-2025: HMA-EMA joint Big Data Steering Group